A transcriptomic analysis of acute hepatotoxicity induced by aristolochic acid Ⅰ in mice

Gerui ZHU; Jing WANG; Kai HUANG; Yuan PENG; Chenghai LIU; Yanyan TAO

doi:10.3969/j.issn.1001-5256.2021.10.026

Volume 37 Issue 10

Oct. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(10): 2389-2394

PDF( 2591 KB)

A transcriptomic analysis of acute hepatotoxicity induced by aristolochic acid Ⅰ in mice

DOI: 10.3969/j.issn.1001-5256.2021.10.026

1.
Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2.
Shanghai Key Laboratory of Traditional Chinese Medicine, Shanghai 201203, China

Research funding:

The Special Project for Significant New Drug Research and Development in the Major National Science and Technology Projects of China (2019ZX09201001);

The Science and Technology Innovation Action Plan of the Shanghai Municipal Science and Technology Commission (19401901500);

The Three-Year Action Plan of for the Development of TCM in Shanghai (ZY-[2018-2020]-CCCX-5001)

Received Date: 2021-03-04
Accepted Date: 2021-05-13
Published Date: 2021-10-20

Abstract

Abstract

Objective To investigate the molecular mechanism of aristolochic acid Ⅰ (AAⅠ) inducing acute hepatotoxicity in mice. Methods A total of 15 male C57BL/6 mice were randomly divided into normal group with 6 mice and treatment group with 9 mice. The mice in the treatment group were given intraperitoneal injection of AAⅠ at a dose of 20 mg/kg for 5 consecutive days and were sacrificed to collect samples on day 6. The serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured, and HE staining was used to observe liver histological changes; three liver tissue samples were randomly selected from each group, and RNA was extracted for high-throughput transcriptome sequencing. Bioinformatics analysis and functional prediction were used to screen out differentially expressed genes, and quantitative real-time PCR (qRT-PCR) was used for validation. The t-test was used for comparison of continuous data between two groups. Results Compared with the normal group, the treatment group had significant increases in the activities of ALT and AST (t=4.331 and 4.947, both P < 0.01), as well as disordered structure of hepatic lobules and spotted necrosis in hepatic lobules shown by HE staining. A total of 1352 differentially expressed genes were obtained based on the screening conditions of logFC > 2 and P < 0.05, among which there were 703 upregulated genes and 649 downregulated genes. The GO and KEGG enrichment analyses of these differentially expressed genes showed significant enrichment in GO terms (such as small molecular catabolism, immune response involving neutrophils, cytoplasmic vesicle lumen in secretory granules, cytoplasmic vesicle lumen, extracellular structural organization, and extracellular matrix) and KEGG pathways (such as chemical carcinogenesis, retinol metabolism, arachidonic acid metabolism, steroid hormone biosynthesis, transcriptional dysregulation in cancer, protein digestion and absorption, regulation of TRP channel by inflammatory mediators, drug metabolism, complement and coagulation cascade, glutathione metabolism, and the PPAR signaling pathway). A cluster analysis (P < 0.05) showed that significantly downregulated genes included Srd5a1, Lipc, Aqp8, Hba-a1, Slco1a1, and Pklr, which were validated by qRT-PCR (all P < 0.05). Conclusion AA Ⅰ can lead to significant acute hepatotoxicity, which mainly involves the processes such as chemical carcinogenesis, retinol metabolism, arachidonic acid metabolism, steroid hormone biosynthesis, and transcriptional dysregulation in cancer.
- ARISTOLOCHIC ACID,
- Transcriptome,
- Chemical and Drug Induced Liver Injury,
- Mice, Inbred C57BL

FullText(HTML)

References(33)

References

[1]	MICHL J, INGROUILLE MJ, SIMMONDS MS, et al. Naturally occurring aristolochic acid analogues and their toxicities[J]. Nat Prod Rep, 2014, 31(5): 676-693. DOI: 10.1039/c3np70114j.
[2]	KUMAR V, POONAM, PRASAD AK, et al. Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities[J]. Nat Prod Rep, 2003, 20(6): 565-583. DOI: 10.1039/b303648k.
[3]	ZHANG H, LIU R, AN Z, et al. Aristolactam-type alkaloids and aristolochic acids from Aristolochia moupinensis and Aristolochia cathcartii[J]. Biochem Syst Ecol, 2016, 65: 198-201. DOI: 10.1016/j.bse.2016.02.028.
[4]	JELAKOVIĆ B, KARANOVIĆ S, VUKOVIĆ-LELA I, et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid[J]. Kidney Int, 2012, 81(6): 559-567. DOI: 10.1038/ki.2011.371.
[5]	GUO MZ, YANG S, ZHAO LL. Transcriptome analysis method based on RNA-Seq[J]. Computer Science, 2020, 47(z2): 35-39. DOI: 10.11896/jsjkx.200600057. 郭茂祖, 杨帅, 赵玲玲. 基于RNA-Seq的转录组分析方法[J]. 计算机科学, 2020, 47(z2): 35-39. DOI: 10.11896/jsjkx.200600057.
[6]	NG A, POON SL, HUANG MN, et al. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia[J]. Sci Transl Med, 2017, 9(412): eaan6446. DOI: 10.1126/scitranslmed.aan6446.
[7]	JIANG Z, ZHOU X, LI R, et al. Whole transcriptome analysis with sequencing: Methods, challenges and potential solutions[J]. Cell Mol Life Sci, 2015, 72(18): 3425-3439. DOI: 10.1007/s00018-015-1934-y.
[8]	VANHERWEGHEM JL, DEPIERREUX M, TIELEMANS C, et al. Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs[J]. Lancet, 1993, 341(8842): 387-391. DOI: 10.1016/0140-6736(93)92984-2.
[9]	JADOT I, DECLÈVES AE, NORTIER J, et al. An integrated view of aristolochic acid nephropathy: Update of the literature[J]. Int J Mol Sci, 2017, 18(2). DOI: 10.3390/ijms18020297.
[10]	BALACHANDRAN P, WEI F, LIN RC, et al. Structure activity relationships of aristolochic acid analogues: Toxicity in cultured renal epithelial cells[J]. Kidney Int, 2005, 67(5): 1797-1805. DOI: 10.1111/j.1523-1755.2005.00277.x.
[11]	LU ZN, LUO Q, ZHAO LN, et al. The mutational features of aristolochic acid-induced mouse and human liver cancers[J]. Hepatology, 2020, 71(3): 929-942. DOI: 10.1002/hep.30863.
[12]	LI J, DING Z, WANG Z, et al. Androgen regulation of 5α-reductase isoenzymes in prostate cancer: Implications for prostate cancer prevention[J]. PLoS One, 2011, 6(12): e28840. DOI: 10.1371/journal.pone.0028840.
[13]	LEWIS MJ, WIEBE JP, HEATHCOTE JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma[J]. BMC Cancer, 2004, 4: 27. DOI: 10.1186/1471-2407-4-27.
[14]	KAPP FG, SOMMER A, KIEFER T, et al. 5-alpha-reductase type I (SRD5A1) is up-regulated in non-small cell lung cancer but does not impact proliferation, cell cycle distribution or apoptosis[J]. Cancer Cell Int, 2012, 12(1): 1. DOI: 10.1186/1475-2867-12-1.
[15]	DOWMAN JK, HOPKINS LJ, REYNOLDS GM, et al. Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice[J]. Endocrinology, 2013, 154(12): 4536-4547. DOI: 10.1210/en.2013-1592.
[16]	ANDRÉS-BLASCO I, HERRERO-CERVERA A, VINUÉ Á, et al. Hepatic lipase deficiency produces glucose intolerance, inflammation and hepatic steatosis[J]. J Endocrinol, 2015, 227(3): 179-191. DOI: 10.1530/JOE-15-0219.
[17]	DOOLITTLE MH, WONG H, DAVIS RC, et al. Synthesis of hepatic lipase in liver and extra hepatic tissues[J]. J Lipid Res, 1987, 28(11): 1326-1334. DOI: 10.1016/S0022-2275(20)38591-6
[18]	HOMANICS GE, DE SILVA HV, OSADA J, et al. Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene[J]. J Biol Chem, 1995, 270(7): 2974-2980. DOI: 10.1074/jbc.270.7.2974.
[19]	MARINELLI RA, LEHMANN GL, SORIA LR, et al. Hepatocyte aquaporins in bile formation and cholestasis[J]. Front Biosci (Landmark Ed), 2011, 16: 2642-2652. DOI: 10.2741/3877.
[20]	MATSUZAKI T, TAJIKA Y, ABLIMIT A, et al. Aquaporins in the digestive system[J]. Med Electron Microsc, 2004, 37(2): 71-80. DOI: 10.1007/s00795-004-0246-3.
[21]	JABLONSKI EM, MATTOCKS MA, SOKOLOV E, et al. Decreased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma[J]. Cancer Lett, 2007, 250(1): 36-46. DOI: 10.1016/j.canlet.2006.09.013.
[22]	YANG YJ, LIU L, XU M, et al. Significance of regulating liver transporters in the prevention and treatment of liver diseases[J]. West China J Pharma Sci, 2020, 35(3): 316-324. DOI: 10.13375/j.cnki.wcjps.2020.03.018. 杨玉洁, 刘蕾, 徐苗, 等. 调控肝脏转运体对肝脏疾病防治的意义[J]. 华西药学杂志, 2020, 35(3): 316-324. DOI: 10.13375/j.cnki.wcjps.2020.03.018.
[23]	WANG H, CHEN H, OUYANG ZM, et al. Correlation of the protein expression of organic anion transport polypeptide 1 and multidrug resistance-associated protein 2 on the surface of hepatocyte membrane with signal intensity on Gd -EOB -DTPA -enhanced magnetic resonance imaging in dogs with acute liver failure[J]. J Clin Hepatol, 2020, 36(8): 1788-1793. DOI: 10.3969/j.issn.1001-5256.2020.08.022. 王昊, 陈好, 欧阳中敏, 等. 急性肝衰竭犬模型肝细胞膜表面OATP1及MRP2蛋白表达与钆塞酸二钠增强MRI信号强度的相关性分析[J]. 临床肝胆病杂志, 2020, 36(8): 1788-1793. DOI: 10.3969/j.issn.1001-5256.2020.08.022.
[24]	GEIER A, KIM SK, GERLOFF T, et al. Hepatobiliary organic anion transporters are differentially regulated in acute toxic liver injury induced by carbon tetrachloride[J]. J Hepatol, 2002, 37(2): 198-205. DOI: 10.1016/s0168-8278(02)00108-3.
[25]	MAZUREK S. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells[J]. Int J Biochem Cell Biol, 2011, 43(7): 969-980. DOI: 10.1016/j.biocel.2010.02.005.
[26]	LIU WR, TIAN MX, YANG LX, et al. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma[J]. Oncotarget, 2015, 6(2): 846-861. DOI: 10.18632/oncotarget.2749.
[27]	NGUYEN A, LOO JM, MITAL R, et al. PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis[J]. J Clin Invest, 2016, 126(2): 681-694. DOI: 10.1172/JCI83587.
[28]	KJELDSEN L, JOHNSEN AH, SENGELØV H, et al. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase[J]. J Biol Chem, 1993, 268(14): 10425-10432.
[29]	BORKHAM-KAMPHORST E, van de LEUR E, ZIMMERMANN HW, et al. Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis[J]. Biochim Biophys Acta, 2013, 1832(5): 660-673. DOI: 10.1016/j.bbadis.2013.01.014.
[30]	CHEN F, HE JL, ZHENG M, et al. Complementary laboratory indices for predicting the disease status of patients with hepatitis B virus infection[J]. J Viral Hepat, 2013, 20(8): 566-574. DOI: 10.1111/jvh.12067.
[31]	ARIZA X, GRAUPERA I, COLL M, et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis[J]. J Hepatol, 2016, 65(1): 57-65. DOI: 10.1016/j.jhep.2016.03.002.
[32]	VAŠÁK M, MELONI G. Chemistry and biology of mammalian metallothioneins[J]. J Biol Inorg Chem, 2011, 16(7): 1067-1078. DOI: 10.1007/s00775-011-0799-2.
[33]	NAGAMINE T, NAKAJIMA K. Significance of metallothionein expression in liver disease[J]. Curr Pharm Biotechnol, 2013, 14(4): 420-426. DOI: 10.2174/1389201011314040006.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(6)

1.	程庆兵，汪海宣，郑正，袁杰，杨彬，王玮，张亚中. 超高效液相色谱-串联质谱法测定丹桂香颗粒中马兜铃酸Ⅰ. 化学分析计量. 2024(11): 52-57 .
2.	沈婷婷，朱哿瑞，王帆，孙鑫，黄恺，彭渊，陶艳艳，刘成海. 基因表达谱分析非酒精性脂肪性肝病中谷胱甘肽转移酶的作用. 临床肝胆病杂志. 2023(01): 89-96 . 本站查看
3.	王义翠，刘延鑫，林华忠，魏炳琦，刘曹露，周茜如，赵梦瑶，徐华明. 四氯化碳诱导慢性肝损伤模型小鼠的转录组学分析. 黑龙江畜牧兽医. 2023(05): 65-69 .
4.	朱哿瑞，皮亚妮，王静，黄恺，彭渊，陈高峰，刘成海，陶艳艳. 黄芪提取物调节IL-6/STAT3信号通路治疗马兜铃酸Ⅰ诱导肝肾损伤小鼠模型的效果观察. 临床肝胆病杂志. 2023(08): 1903-1910 . 本站查看
5.	庞逸辉，李岳，张宪. 高效液相色谱法测定杜仲壮骨丸中马兜铃酸A. 化学分析计量. 2022(06): 50-53 .
6.	赵晨阳，吴倩，张云波，李刚，那晓琳. 苯并[b]荧蒽亚急性经口染毒的大鼠肝脏毒性以及转录组改变. 环境卫生学杂志. 2022(11): 777-784+789 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (853) PDF downloads(48)

A transcriptomic analysis of acute hepatotoxicity induced by aristolochic acid Ⅰ in mice

DOI: 10.3969/j.issn.1001-5256.2021.10.026